You are here

Research Projects

Researcher: Mark Burkard, MD, PhD, University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
May 10, 2018
Researcher: Seema Khan, MD, Northwestern University, Chicago, IL, Joseph Michael Guenther, MD, St. Elizabeth HealthCare, Edgewood, KY, Amy Degnim, MD, Mayo Clinic, Rochester, MN, Melissa Pilewskie, MD, Memorial Sloan Kettering Cancer Center, New York, NY, E. Shelley Hwang, MD, Duke University, Durham, NC, Stephen Grobmyer, MD, Cleveland Clinic, Cleveland, OH
February 16, 2018
Researcher: Laura Esserman, MD, MBA, University of California, San Francisco, CA and her partners from the Athena Breast Health Network (a collaboration across the five University of California Medical Centers and Sanford Health)
February 16, 2018
Researcher: Tonia Poteat, PhD, and Lorraine T. Dean, ScD of Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
January 12, 2018
Researcher: Carolyn Westhoff, MD, Columbia University, New York, NY
August 9, 2017

The purpose of this study is to learn how two different medications affect the breast: an estrogen-free selective progesterone-receptor modulator called UPA vs. a low-dose oral contraceptive pill. This is a randomized, phase I clinical trial. Participants have a 50% chance of receiving the UPA pill, and 50% chance of receiving the low-dose oral

Study Abstract

Breast cancer accounts for almost a quarter of all cancers in women. It is estimated that in the U.S. in 2014 more than 230,000 women were diagnosed with the disease and 40,000 died of the disease. Tamoxifen is an effective chemopreventive agent; however, it is not widely used, in part due to its increased risks of endometrial cancer and venous thromboembolism. The United States Preventive Services Task Force recommends tamoxifen use only for those at high risk of breast cancer. There is an urgent need to develop acceptable means of preventing the disease both for high risk and average risk women.

The proposed study is a clinical trial in premenopausal women aged 18-40 to evaluate the capacity of daily Ulipristal Acetate (UPA) to reduce breast epithelial cell proliferation and to measure its effect compared to that found with a combined estrogen-progestin oral contraceptive (COC). UPA is a selective progesterone receptor modulator (SPRM) in use as daily medication up to 12 months for the treatment of menorrhagia due to uterine fibroids, and is currently in trials in the U.S. to evaluate its use as a daily contraceptive. The proposed study will allow us to investigate the potential of UPA to reduce breast cell proliferation and possibly breast cancer risk if used over an extended period of time.

We will compare breast cell proliferation, as measured by Ki67 expression in breast biopsies, at the end of 3 months treatment to baseline values in the 2 groups (UPA and COC). We will also compare the changes in the 2 groups to each other. The comparison of the effect of UPA to that of a conventional COC is because of UPA’s potential use as a daily contraceptive.

Cell proliferation in the breast occurs throughout the menstrual cycle and is roughly twice as high in the luteal phase (elevated progesterone phase) of the cycle. The actions of hormones on the breast are rapid and an anti-progestin such as UPA, which will block the action of progesterone in the breast would be predicted to quickly lower breast cell proliferation in premenopausal women. Effects of UPA on the endometrium continue to be studied and are reassuring. COC use has not been found to lower breast cell proliferation and is not associated with any decrease in risk of breast cancer.

The changes in breast cell proliferation will also be compared to changes seen on breast MRI. If these are highly correlated future studies will be able to be done without the need for breast biopsies.

Researcher: Thomas Mack, MD, MPH, University of Southern California, Los Angeles
July 12, 2017

This study aims to identify non-genetic factors that increase or decrease breast cancer risk in twins. This information could help researchers identify ways to help prevent breast cancer from occurring.

Study Abstract

In any population, with the presence of more than 100 genetic determinants, most breast cancer cases are likely to carry one, yet community occurrence is dominated by non-genetic risk factors. Adult identical twin women are representative of the population of origin in both genetic and non-genetic factors. However, when one gets breast cancer, the lifetime risk to the co-twin is much higher than expected on the basis of risk to an ordinary sister. Even so, only about a quarter of such co-twins become affected, and those that are become diagnosed years later. Thus affected pairs, whether breast cancer discordant or concordant, differ in the level of penetrance, and since the genetic determinants carried by concordant cases are unlikely to differ from those in discordant cases, the difference between such affected pairs, given the same genetic determinants, also reflects a different level of penetrance. We propose to verify the identity of genetic determinants between discordant and concordant pairs (using the Illumina OncoArray 500K), and to document the existence and timing of exogenous determinants of higher penetrance. This will be within discordant pairs, between the members of concordant pairs differing in age at diagnosis, and between cases from discordant and concordant pairs with the same or similar genotype. We will use adult twins’ documented ability to accurately recall childhood differences between themselves in behaviors, environmental exposures, and given current emphasis on adolescence, the rate of development.

Researcher: David Spiegel, MD, Amit Etkin, MD, PhD, James Gross, PhD, and Allison Kurian, MD, MSc, Stanford University School of Medicine. The study is funded by the National Cancer Institute.
June 7, 2017

The goal of this study is to better understand what women are thinking about and feeling as they decide on their cancer treatments. The results of this study may help researchers develop new interventions that may better assist women newly diagnosed with breast cancer with their treatment decisions.

Study Abstract

Women diagnosed with breast cancer are choosing bilateral mastectomy (BLM) at increasing rates, currently 14.3%, and 33% of those under 40. This is happening despite evidence that there is no survival benefit from BLM, along with surgical complications and other serious medical and personal costs, compared with more conservative approaches. Women’s anxiety about recurrence is critical to this decision, so their choice may in large part reflect the way they experience and regulate affect. To understand the neurobiological and affective determinants of the choice of BLM, and thereby identify future opportunities for new interventions, we propose to examine the relationship between affect reactivity and regulation and women’s decisions regarding BLM after initial diagnosis of breast cancer. We will also examine the impact of affect management and treatment decisions on subsequent psychosocial functioning. Our Specific Aims are to: 1) Examine affect reactivity and regulation among women with a recent diagnosis of breast cancer in comparison to healthy controls; 2) Relate affect reactivity and regulation to choice of BLM; and 3) Assess long term functional consequences of BLM decision and affect reactivity and regulation. This study will provide an empirical basis for better assisting patients in making difficult but important choices regarding breast cancer treatment alternatives.

Researcher: Patricia A. Ganz, MD, Julienne Bower, PhD, and Catherine Crespi, PhD, at University of California, Los Angeles; Ann Partridge, MD, MPH and Hadine Jaffe, MD, MSc at Dana-Farber Cancer Institute; and Antonio Wolff, MD, Katherine Smith, PhD, and Elissa Bantug, MHS, at Johns Hopkins University
May 3, 2017

The purpose of this study is to see how well two different types of group programs—mindfulness-meditation classes and survivorship education classes—meet the needs of young survivors. Up to 360 women will take part in this study.

Study Abstract

This is a multi-site, randomized, three arm, Phase III trial that will evaluate the efficacy of two distinct types of group interventions that are specially designed for younger women who are more than 6 months post initial treatment for breast cancer. The first intervention is a mindfulness meditation-based intervention focused on improving psychological, behavioral, and biological function in younger breast cancer survivors that is adapted from an institutional program in place for the general public at UCLA’s Semel Institute for Neuroscience and Human Behavior. The second intervention is a 6-week didactic group-based survivorship education seminar series that will review specific topics of importance to younger breast cancer survivors including: quality of life after breast cancer; medical management and quality of care post treatment; relationships and work-life balance; body image, sexuality and fertility; energy balance, nutrition, and physical activity; cancer in the family, genetics, and related issues. This curriculum has been adapted from two studies already completed by the investigators, and has a standardized slide set, and will be delivered by a health educator or advanced practice nurse at each of the participating institutions. There will be a maintenance period that follows the 6-week group interventions to help sustain both mindfulness and health behaviors. The third arm of the study (Arm C) will include a usual care group with delayed intervention offered to the participants after they have completed parallel outcome assessments alongside the participants receiving the two interventions (Arm A and Arm B), but not until the end of data collection (6 months after the post-intervention assessments for the cohort).

Researcher: Christine Miaskowski, PhD, RN, University of California, San Francisco
April 25, 2017

This study is designed to identify both signs and symptoms of breast cancer-related lymphedema and genetic factors that predict whether patients are at increased risk for developing lymphedema. The researchers intend to use the results to develop and test new approaches to prevent or reduce the risk of lymphedema developing following breast cancer treatment.

Resulting Publications:
Chemotherapy-Induced Neuropathy in Cancer Survivors

Study Abstract

Lymphedema (LE) following treatment for breast cancer is the most common form of secondary LE in the industrialized world. It occurs in 20% to 87% of patients following treatment for breast cancer and results in significant disability. At the present time, the definitive phenotypic, genotypic and epigenotypic predictors that place patients at highest risk for the development of LE are not known. Therefore, the specific aims of this study, in a sample of patients following treatment for breast cancer, are to: determine genetic predictors of LE using a candidate gene approach and evaluate for epigenetic changes, as measured by DNA methylation and subsequent gene expression, in candidate genes associated with the diagnosis of LE. The secondary aims of this study are to: evaluate for latent classes of women with distinct phenotypic predictors of LE; and evaluate for differences in symptoms, functional status, and QOL outcomes between women with and without LE and among the latent classes with LE. The results of this study will provide new information on the underlying mechanisms for LE and allow for the development and testing of novel approaches to prevent or reduce the negative effects of LE.